Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

Rhea-AI Summary

Cyanotech (CYAN) reported Q2 fiscal 2025 financial results with net sales of $5.85M, down 8.3% from $6.37M in Q2 fiscal 2024. The company saw a 39% increase in bulk sales and 156% growth in contract extraction, while packaged goods decreased by 21%. Gross profit margin declined to 25.3% from 32.8%. The quarter resulted in a net loss of $1.15M ($0.16 per share) compared to $797K ($0.13 per share) last year. For the first six months, net sales increased 1.9% to $11.74M, though gross profit margin decreased to 25.2% from 31.4%, with a net loss of $2.35M.

Positive

• Bulk sales increased by 39%
• Contract extraction revenue grew by 156%
• First six months net sales increased by 1.9% to $11.74M

Negative

• Q2 net sales decreased 8.3% to $5.85M
• Q2 gross profit margin declined to 25.3% from 32.8%
• Q2 net loss increased to $1.15M from $797K
• Packaged goods sales decreased by 21%
• First six months gross profit margin declined to 25.2% from 31.4%
• TTM net loss increased to $5.45M from $4.20M

KAILUA KONA, Hawaii--(BUSINESS WIRE)-- Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024.

Commenting on the second quarter fiscal year 2025 results, Cyanotech’s President and Chief Executive Officer, Matthew K. Custer, said:

“In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finished goods were still down by $1.5 million.”

“Bulk inventory, which has a shorter production time, helped drive a 39% increase in sales, and revenue from contract extraction grew by 156%. However, packaged goods, which take longer to restock, saw a 21% decrease due to stock shortages and timing issues, contributing to an overall 8% drop in total sales for the quarter.”

“For the first half of the year, sales were up 2%. While progress with packaged goods has been slower than expected, we’re working quickly to replenish stock and continue promoting our algae-based products farmed in Hawaii’s pristine waters.”

Second Quarter Fiscal 2025

Cyanotech reported net sales of $5,845,000 for the second quarter of fiscal 2025 compared to $6,373,000 for the second quarter of fiscal 2024, a decrease of 8.3%. Gross profit was $1,479,000, with gross profit margin of 25.3%, compared to gross profit of $2,088,000, with gross profit margin of 32.8%. Operating loss for the second quarter of fiscal 2025 was $975,000 compared to operating loss of $632,000 in the same period of the prior year. Net loss for the current fiscal quarter was $1,150,000, or $0.16 per diluted share, compared to net loss of $797,000, or $0.13 per diluted share, for the same period of the prior year.

First Six Months of Fiscal 2025

Cyanotech reported net sales of $11,743,000 for the first six months of fiscal 2025 compared to $11,519,000 for the same period in fiscal 2024, an increase of 1.9%. Gross profit was $2,956,000, with gross profit margin of 25.2%, compared to gross profit of $3,620,000, with gross profit margin of 31.4%. Operating loss for the first six months of fiscal 2025 was $2,016,000 compared to operating loss of $1,841,000 in the same period of the prior year. Net loss for the first six months of fiscal 2025 was $2,352,000, or $0.34 per diluted share, compared to net loss of $2,166,000, or $0.34 per diluted share, for the same period of the prior year.

Trailing Twelve Months

For the trailing twelve months ended September 30, 2024, compared to the trailing twelve months ended September 30, 2023, net sales were $23,295,000 compared to $22,801,000, respectively. Gross profit was $5,280,000, with gross profit margin of 22.7%, compared to $6,771,000 and 29.7%. Net loss was $5,452,000, or $0.80 per diluted share, compared to net loss of $4,195,000, or $0.67 per diluted share.

Please review the Company’s Form 10-Q for the period ended September 30, 2024 for more detailed information.

---------------

— Cyanotech will host a virtual broadcast at 8:00 PM ET on Wednesday, November 13, 2024 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to questions@cyanotech.com before 12 p.m. (noon) ET on Wednesday, November 13, 2024. The Company will respond only to relevant questions relating to the Company’s second quarter fiscal 2025 financial performance and will not be accepting any questions or comments during the broadcast.

To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.

---------------

About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 30 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company’s mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech’s BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity*. All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe (“GRAS”) for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the Food and Drug Administration. Visit www.cyanotech.com for more information.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.

Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company’s Form 10-Q for the second quarter fiscal 2025 ended September 30, 2024, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such, the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.

CYANOTECH CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited)
	September 30, 2024				March 31, 2024
ASSETS
Current assets:
Cash	$	780			$	707
Accounts receivable, net of allowance for credit losses of $11 as of September 30, 2024 and March 31, 2024		1,592				2,102
Inventories		7,185				7,313
Prepaid expenses and other current assets		568				469
Total current assets		10,125				10,591
Equipment and leasehold improvements, net		9,505				10,109
Operating lease right-of-use assets, net		4,161				4,284
Other assets		122				128
Total assets	$	23,913			$	25,112
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,132			$	1,439
Accrued expenses		619				757
Customer deposits		272				198
Operating lease obligations, current portion		533				530
Short term debt - bank		1,000				1,240
Line of credit – related party		2,000				1,250
Current maturities of long-term debt		3,019				3,140
Total current liabilities		9,575				8,554
Long-term debt – related party		1,000				1,000
Long-term operating lease obligations		3,646				3,744
Total liabilities		14,221				13,298
Commitments and contingencies
Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding		—				—
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 7,142,700 shares at September 30, 2024 and 6,947,246 shares at March 31, 2024		143				139
Additional paid-in capital		34,802				34,576
Accumulated deficit		(25,253	)			(22,901	)
Total stockholders’ equity		9,692				11,814
Total liabilities and stockholders’ equity	$	23,913			$	25,112

CYANOTECH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands) (Unaudited)
	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
Net sales	$	5,845			$	6,373			$	11,743			$	11,519
Cost of sales		4,366				4,285				8,787				7,899
Gross profit		1,479				2,088				2,956				3,620
Operating expenses:
General and administrative		1,244				1,160				2,513				2,434
Sales and marketing		1,073				1,385				2,238				2,661
Research and development		137				175				221				366
Total operating expenses		2,454				2,720				4,972				5,461
Loss from operations		(975	)			(632	)			(2,016	)			(1,841	)
Interest expense, net		(175	)			(163	_			(336	)			(323	)
Loss before income taxes		(1,150	)			(795	)			(2,352	)			(2,164	)
Income tax expense		—				2				—				2
Net loss	$	(1,150	)		$	(797	)		$	(2,352	)		$	(2,166	)
Net loss per share:
Basic	$	(0.16	)		$	(0.13	)		$	(0.34	)		$	(0.34	)
Diluted	$	(0.16	)		$	(0.13	)		$	(0.34	)		$	(0.34	)
Shares used in calculation of net loss per share:
Basic		7,004				6,366				6,976				6,328
Diluted		7,004				6,366				6,976				6,328

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112749954/en/

Jennifer Rogerson

(808) 334-9455

investorrelations@cyanotech.com

Source: Cyanotech Corporation

FAQ

What was Cyanotech's (CYAN) revenue for Q2 fiscal 2025?

Cyanotech reported net sales of $5,845,000 for Q2 fiscal 2025, an 8.3% decrease from $6,373,000 in Q2 fiscal 2024.

How much did Cyanotech (CYAN) lose per share in Q2 fiscal 2025?

Cyanotech reported a net loss of $0.16 per diluted share in Q2 fiscal 2025, compared to a net loss of $0.13 per diluted share in the same period last year.

What was Cyanotech's (CYAN) gross profit margin in Q2 fiscal 2025?

Cyanotech's gross profit margin was 25.3% in Q2 fiscal 2025, down from 32.8% in Q2 fiscal 2024.

How did Cyanotech's (CYAN) bulk sales perform in Q2 fiscal 2025?

Cyanotech's bulk sales increased by 39% in Q2 fiscal 2025, while contract extraction revenue grew by 156%.